278. Huge lymphatic malformation with cervicofacial lesion Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 19 Drugs : 22 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63

Drugs and their primary sponsors and trial info
Bleomycin   
   Fujino Akihiro
      2016   -   JPRN-jRCTs031180265   Japan;
CERC-006   
   Cerecor Inc
      2021   Phase 1   NCT04994002   United States;
Indocyanine green   
   Aitaro Takimoto
      2017   Phase 2   JPRN-jRCTs041190036   Japan;
   Nagoya University Graduate School ofMedicine
      2017   -   JPRN-UMIN000025845   Japan;
L04AA10   
   CHRU TOURS
      2019   Phase 2   EUCTR2019-001530-33-FR   France;
MRI   
   University Hospital, Lille
      2018   Phase 2   NCT03243019   France;
OK432   
   Richard JH Smith
      1998   Phase 4   NCT03427619   United States;
Oral sirolimus   
   Children's Hospital of Fudan University
      2021   Phase 4   NCT04921722   China;
PTX-022   
   Palvella Therapeutics, Inc.
      2021   Phase 2   NCT05050149   United States;
Percutaneous sirolimus   
   Children's Hospital of Fudan University
      2021   Phase 4   NCT04921722   China;
Picibanil   
   University of Iowa
      2000   Phase 2/Phase 3   NCT00010452   United States;
Propranolol   
   University of Tokyo
      2012   Phase 2   JPRN-UMIN000008498   Japan;
Rapamycin dosage   
   University Hospital, Lille
      2018   Phase 2   NCT03243019   France;
Selenium   
   Medical College of Wisconsin
      2010   Phase 1   NCT01212965   United States;
Sildenafil   
   Beijing Children's Hospital
      2014   -   ChiCTR-OPC-16008702   China;
Sildenafil 20 mg tablets   
   Stanford University
      2015   Phase 2   NCT02335242   United States;
Sirolimus   
   Children's Hospital Medical Center, Cincinnati
      2009   Phase 2   NCT00975819   United States;
   Gifu University
      2017   -   JPRN-UMIN000030522   Japan;
   Gifu University Hospital
      2020   Phase 3   JPRN-UMIN000038973   Japan;
   Medical University of South Carolina
      2021   Phase 2   NCT04861064   United States;
Sirolimus 0, crème   
   CHRU TOURS
      2019   Phase 2   EUCTR2018-001359-11-FR   France;
Sirolimus 1mg/mL   
   CHRU TOURS
      2019   Phase 2   EUCTR2019-001530-33-FR   France;
Sirolimus Oral Liquid Product 1mg/mL   
   University Hospital, Tours
      2020   Phase 2   NCT04128722   France;
Topical Sirolimus   
   University Hospital, Tours
      2019   Phase 2   NCT03972592   France;
Topical Vehicle   
   University Hospital, Tours
      2019   Phase 2   NCT03972592   France;
VT30   
   Venthera, Inc., a BridgeBio company
      2020   Phase 1/Phase 2   NCT04409145   United States;
Water   
   Fujino Akihiro
      2016   -   JPRN-jRCTs031180265   Japan;